Where does C2N Diagnostics rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), C2N Diagnostics ranks #45,409 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does C2N Diagnostics hold?

C2N Diagnostics holds 5 US utility patents granted between 2018 and 2025, spanning 6 technology areas.

What is C2N Diagnostics's Innovation Score?

C2N Diagnostics has an Innovation Score of 21.4 out of 100 (8th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is C2N Diagnostics's patent grant rate increasing or decreasing?

C2N Diagnostics's recent grant velocity is -67% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for C2N Diagnostics's patents?

C2N Diagnostics's patents average 11.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the C2N Diagnostics patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

C2N Diagnostics

Q: What technology areas does C2N Diagnostics focus on?

C2N Diagnostics's top technology area is G01N (Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties) with 4 patents. Grants appear in 6 CPC subclasses total.

USPTO PatentsView assignee record - 5 granted patents across 6 technology areas, recorded in grant years 2018–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: G01N (Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, C2N ranks #45,409 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 6 technology areas.

#45,409
of 49,997 US assignees by volume: 8th percentile
by Innovation Score (21.4/100): 11.0
avg claims per patent: -67%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R45409 · US Corporation #45,409 · 5 grants

GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 5 grants
BOTTOM-DECILE #45,409/49,997
PHOTO-FINISH C2a-sec
CPC-NARROW G01N · 6 areas
INNOV-THIN 21.4/100
CLAIMS-PAR 11.0 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -67% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: C2a-sec, Ltd (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
C2N Diagnostics · this assignee

21
3D Lighting… · lowest

7

What this shows C2N's Innovation Score is 21.4/100 (8th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where C2N's grants concentrate

C2N Diagnostics is a focused PatentsView assignee: 6 CPC subclasses with 80% of grants classified under G01N (Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties). Peak complete grant year is 2019 (2 grants) versus a trough of 1 in 2018. By volume, C2N sits between C.E. Niehoff & Co. and C7 Sugar GMBH.

C E Niehoff &

5
C M T Utensili S…

5
C P Medical

5
C2a-sec

5
C3 Jian

5
C360

5
C4 Carbides

5
C7 Sugar

5
C2N Diagnostics ◀

5

What this shows C2N holds 5 patents at rank #45,419, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near C2N

By rank, the assignees closest to #45,419 in granted patent volume.

Leaders in G01N (Investigating OR Analysing Materials BY Determining Their…)

Other assignees with the most granted patents in C2N's primary technology class.

C2N's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

21 8th percentile higher than 8% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2018–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table

C2N Diagnostics patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2018	1	20.0%
2019	2	40.0%
2021	1	20.0%
2025partial year	1	20.0%

Which technologies does C2N Diagnostics patent most?

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 4

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 3

C07K - Peptides 1

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 1

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 1

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 1

Top 6 of 6 technology areas

Where it ranks

Overall rank by patents

#45,409

of 49,997 tracked assignees

Innovation Score

21.4 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

C2N Diagnostics's patent record in context - here's where to go next.

C2N Diagnostics's lead technology class is G01N (Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties), 80% of its portfolio - see every assignee active in that class. Explore G01N
Ranked #45,409 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare C2N Diagnostics against C.E. Niehoff & Co., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 21.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.